Ravulizumab Treatment Outcomes in Patients With Generalized Myasthenia Gravis
The Polish multicentre observational (non-interventional) study aiming to collect data on the management and clinical outcomes of patients with gMG that received ravulizumab.
Myasthenia Gravis, Generalized
DRUG: Ravulizumab
Change from baseline in Myasthenia Gravis-Activities of Daily Living (MG-ADL) total score, at 6 month
Change from baseline in Myasthenia Gravis-Activities of Daily Living (MG-ADL) total score, at month 12, 24, 36|Change from baseline in MG-ADL subcomponent scores, Subcomponent scores - bulbar, limbs, respiratory, and ocular, at month 6, 12, 24, 36|Change from baseline in Myasthenia Gravis (MG) composite scale, at month 6, 12, 24, 36|Proportion of patients who achieved response, Response - an improvement of ≥ 2 points in MG-ADL total score (proportion of patients with ≥ 3 improvement will be also presented), at month 6, 12, 24, 36|Change in the Revised 15-Component Myasthenia Gravis Quality of Life (MG-QOL15r) score, at month 6, 12, 24, 36|Change from baseline in Work Productivity and Activity Impairment: Specific Health Problem (WPAI:SHP), at month 6, 12, 24, 36|Change from baseline in Patient Global Impression of Change (PGI-C), at month 6, 12, 24, 36|Change from baseline in Neuro-Qol Short Form v1.0 - Fatigue, at month 6, 12, 24, 36|Change from baseline in Patient Health Questionnaire - 9 (PHQ-9), at month 6, 12, 24, 36
The Polish, prospective, multicenter, observational, cohort study designed to collect longitudinal data on the management and clinical outcomes of patients with gMG naive to complement inhibitors who received ravulizumab in the scope of routine clinical practice within the frames of National Drug Program (NDP) for up to 42 months (\~ 6 months baseline and \~36 months follow-up).